Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 1:14 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1897–1920 of 5,924 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: mRI Clear all

Conditions: Squamous Neck Carcinoma of the Head and Neck Cancer (SCCHN)
Interventions: Tirapazamine, Cisplatin, 5-fluorouracil, Radiotherapy (RT); Drug · Radiation
Lead sponsor: Stanford University; Other
Eligibility: 17 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2005
U.S. locations: 2
States / cities: Palo Alto, California • Stanford, California

Conditions: Patients Undergoing Cardiac Surgery
Interventions: Not listed
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Lung Cancer
Interventions: fluorine F 18 FEQA + positron emission tomography; Procedure
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Prostate Cancer
Interventions: Focal Laser Ablation; Device
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 40 Years to 85 Years · Male only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Cystic Fibrosis
Interventions: PFP; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 99 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions: Autologous Anti-CD83 CAR T-cells, Biospecimen Collection, Chest Radiography, Computed Tomography, Cyclophosphamide, Echocardiography, Fludarabine Phosphate, Hydroxyurea, Leukapheresis, Lumbar Puncture, Positron Emission Tomography, Questionnaire Administration; Drug · Procedure · Other
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Unipolar Depression
Interventions: MRI, MagPro TMS stimulator and coil, Thymatron (R) System IV paired with 4X1 HDECT; Device
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 22 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Peripheral Artery Disease
Interventions: Simvastatin, Ezetimibe, Simvastatin/Ezetimibe; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 30 Years to 85 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Ventricular Function
Interventions: three-dimensional echocardiography; Diagnostic Test
Lead sponsor: Boston Children's Hospital; Other
Eligibility: Up to 18 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions: Biopsy Procedure, Biospecimen Collection, Bone Scan, Computed Tomography, Fludeoxyglucose F-18, Gallium Ga 68 Gozetotide, Lutetium Lu 177 Vipivotide Tetraxetan, Positron Emission Tomography, Single Photon Emission Computed Tomography, Vorinostat; Procedure · Other · Drug
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: Male only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Advanced Microsatellite Stable Colorectal Carcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma, Stage III Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8
Interventions: Biospecimen Collection, Computed Tomography, Fluorouracil, Irinotecan, Ivonescimab, Leucovorin Calcium, Magnetic Resonance Imaging, Muzastotug; Procedure · Drug · Biological
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Duarte, California

Conditions: Adult Solid Neoplasm, Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Carcinoma, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer
Interventions: Computed Tomography, Fluorothymidine F-18, Laboratory Biomarker Analysis, Pharmacological Study, Positron Emission Tomography, Sunitinib Malate; Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Behavior, Health
Interventions: Radiotracer; Drug
Lead sponsor: Yale University; Other
Eligibility: 28 Years to 70 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Smoking
Interventions: Repetitive transcranial magnetic stimulation, MagStim Rapid2, Sham repetitive transcranial magnetic stimulation; Device
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Ischemic Left Ventricle Systolic Dysfunction, Multivessel Coronary Artery Disease
Interventions: Cardiac Magnetic Resonance Imaging; Diagnostic Test
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 3
States / cities: Brooklyn, New York • Flushing, New York • New York, New York

Conditions: Uterine Cervical Neoplasms
Interventions: MR Spectroscopy, Fat-Saturation and Diffusion-Weighted Imaging, Dynamic Contrast Enhancement MRI (MR-DCE), Diffusion Tensor Imaging (DTI); Device
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Triple-Negative Breast Carcinoma, Unresectable Malignant Solid Neoplasm
Interventions: BET Bromodomain Inhibitor ZEN-3694, Binimetinib, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 4
States / cities: Boston, Massachusetts • Galveston, Texas • Houston, Texas

Conditions: Schizophrenia Spectrum and Other Psychotic Disorders
Interventions: Risperidone; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 35 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Heart Failure Preserved Ejection Fraction, Epicardial Adipose Tissue
Interventions: GLP-1RA; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years to 90 Years
Enrollment: 192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Prostate Carcinoma
Interventions: Biopsy of Prostate, Biospecimen Collection, Computed Tomography, Flotufolastat F-18 Gallium, Positron Emission Tomography; Procedure · Radiation
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years to 90 Years · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2037
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Healthy, Aging
Interventions: MRI, TCD; Device
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 20 Years to 64 Years
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Cerebrovascular Circulation, Magnetic Resonance Imaging
Interventions: MRI; Device
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 20 Years to 40 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Renal Cancer, Kidney Cancer, Renal Cell Carcinoma, Inferior Vena Cava Thrombosis
Interventions: Axitinib, Pembrolizumab; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 3
States / cities: Aurora, Colorado • Highlands Ranch, Colorado • Lone Tree, Colorado

Conditions: Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified, Recurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Recurrent Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory Grade 3b Follicular Lymphoma, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified, Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions: Biopsy, Biospecimen Collection, Carboplatin, Computed Tomography, Etoposide, Ifosfamide, Lenalidomide, Positron Emission Tomography, Tafasitamab; Procedure · Drug · Biological
Lead sponsor: David Bond, MD; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Columbus, Ohio

Search by objective public record fields.

Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer

Measurement of Pulmonary Transit Time by Echocardiography: Comparison With Cardiac MRI

Fluorine F 18 FEQA in Patients With Stage III or Stage IV Non-Small Cell Lung Cancer and in Healthy Participants

Focal Laser Ablation of Prostate Cancer

19F MRI to Evaluate Regional Ventilation in Healthy Subjects and Subjects With Cystic Fibrosis

Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Title: Safety and Feasibility of Individualized Low Amplitude Seizure Therapy (iLAST)

Comprehensive Magnetic Resonance of Peripheral Arterial Disease

Assessment of Right Ventricular Volume in Pediatric Patients

Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer

Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the Treatment of Microsatellite Stable Advanced/Metastatic Colorectal Cancer

Sunitinib Malate in Treating Patients With Unresectable or Metastatic Kidney Cancer or Other Advanced Solid Tumors

Novel in Vivo Synaptic Imaging in Experienced Meditators

Insular Inhibitory Neuromodulation to Reduce Cigarette Craving and Alter Brain Function in Smokers

STICH3C Cardiac Magnetic Resonance Observational Study

MRI (Including Spectroscopy and Fat-Saturations and Diffusion-Weighted Imaging) in Cervical Cancer

Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer

Biomarkers of Conversion Risk and Treatment Response in Early-Stage Schizophrenia

Epicardial Adipose Tissue Composition and Heart Failure With Preserved Ejection Fraction

Comparing a New PSMA Imaging Agent to MRI for Detecting Prostate Cancer, BEACON Trial

Brain Blood Flow: Age and Gender

Brain Blood Flow Responses During Exercise: Younger Cohort

Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus

Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma